Jiao Di, Yang Yang, Wang Kejing, Wang Yaomei
School of Medicine, Zhengzhou University of Industrial Technology, Zhengzhou, China.
Department of Hematology, Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Medicine (Baltimore). 2025 Jan 17;104(3):e41218. doi: 10.1097/MD.0000000000041218.
Parkinson disease (PD) is the second most common neurodegenerative disease, and its incidence is climbing every year, but there is still a lack of effective clinical treatments. In recent years, many studies have shown that ferroptosis plays a key role in the progression of PD. Most importantly, many cellular and animal studies and clinical trials have shown that episodes of PD can be alleviated by inhibiting the ferroptosis process, such as utilizing inhibitors, chelating agents, and others. Here, we review the role of ferroptosis, a new form of cell death, in the pathogenesis of PD, and summarize the therapeutic strategies for targeting ferroptosis in PD, hoping to provide new thinking for the study of PD pathogenesis and the development of therapeutic strategies.
帕金森病（PD）是第二常见的神经退行性疾病，其发病率逐年攀升，但仍缺乏有效的临床治疗方法。近年来，许多研究表明，铁死亡在帕金森病的进展中起关键作用。最重要的是，许多细胞和动物研究以及临床试验表明，通过抑制铁死亡过程，如使用抑制剂、螯合剂等，可以缓解帕金森病的发作。在此，我们综述了一种新的细胞死亡形式——铁死亡在帕金森病发病机制中的作用，并总结了针对帕金森病中铁死亡的治疗策略，希望为帕金森病发病机制的研究和治疗策略的开发提供新的思路。
